Newsletter | September 18, 2023

09.18.23 -- How To Make The RTO More Productive For Employees


How To Make The RTO More Productive For Employees

As workers return to the office, the workplace will need to be tailored to better support their needs. Some of the considerations — from flexible hybrid options to new kinds of office environments — may inspire more employees to come back in person.

3 Traits For Compliance Execs To Become Business Leaders

Evaluating a wider range of inputs and forming your own strategic viewpoint aligned with business priorities enables you to pivot to being a business leader, rather than an advisor to business leaders.

How Can Executives Work Through Tightened Budgets And Manage Trade-offs While Keeping The Workforce Happy And Motivated?

See the answer from Tim Wright, chairman of the board of directors at Isosceles Pharmaceuticals.


Unboxing Genentech’s New Clinical Supply Center

Genentech’s Clinical Supply Center, which opened in 2022 in South San Francisco, earned the company an ISPE Facility of the Year Award in the Pharma 4.0 category. This Q&A, the third in a series featuring FOYA winners, explores the strategy behind a central manufacturing site for clinical manufacturing.


Optimizing Formulations With Bioavailability Enhancement Technologies

API-sparing development techniques and identification of the appropriate scalable formulation technology to improve drug solubility and enhance oral bioavailability can help increase your chances of success.

Formulation Considerations For Pediatric Populations

By partnering with a CDMO with experience in pediatric formulation, pharmaceutical companies can increase acceptability of their drugs among pediatric patients.

Allogeneic Vs. Autologous Cell Therapy: Deciding On Your Product Strategy

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.

Fixed Dose Combination Drugs

A company was seeking a CDMO partner with the expertise and technological capabilities to combine three drug substances into a fixed dose combination product suitable for adult and pediatric dosing.

Coordinating Launches To Unlock Your Full North American Potential

Explore the benefits and misconceptions of a coordinated launch across North America as well as how an integrated approach can increase patient access and optimize revenue potential.


September 2023 Digital Edition

Inside you will find more on:

  • Big Pharma Exclusive Interviews
  • Startup Struggles
  • Finance Topics
  • Leadership Tips

View the digital edition.


Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director. 

Connect With Life Science Leader: